Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice

Archives of Cardiovascular Diseases

Volumn 107, Issue 3, 2014, Pages 188-200

  Bruckert, Eric ^a   Ferrières, Jean ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CHU RANGUEIL   (France)

Author keywords

Cardiovascular diseases; High blood pressure; Low density lipoprotein cholesterol; Primary prevention; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; HIGH RISK POPULATION; HYPERCHOLESTEROLEMIA; PRESCRIPTION; PRIMARY PREVENTION; RISK BENEFIT ANALYSIS; AGE; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DIABETES COMPLICATIONS; ECONOMICS; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY (TOPIC); MUSCLE DISEASE; PRACTICE GUIDELINE; RISK; SECONDARY PREVENTION;

AGE FACTORS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; EVIDENCE-BASED MEDICINE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; META-ANALYSIS AS TOPIC; MORTALITY; MULTICENTER STUDIES AS TOPIC; MUSCULAR DISEASES; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK; SECONDARY PREVENTION;

EID: 84899416206     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2014.01.011     Document Type: Review

References (78)

1. R. Lozano, M. Naghavi, and K. Foreman et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2095 2128
2. A.S. Go, D. Mozaffarian, and V.L. Roger et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association Circulation 127 2013 e6 e245
3. M. Nichols, N. Townsend, and P. Scarborough et al. Cardiovascular disease in Europe: epidemiological update Eur Heart J 34 2013 3028 3034
4. M. Lazo, R. Hernaez, and M.S. Eberhardt et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994 Am J Epidemiol 178 2013 38 45
5. B.M. Egan, Y. Zhao, and R.N. Axon US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008 JAMA 303 2010 2043 2050
6. Q. Gu, V.L. Burt, and C.F. Dillon et al. Trends in anti-hypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010 Circulation 126 2012 2105 2114
7. P.L. Vervueren, M. Elbaz, and J. Dallongeville et al. Relationships between chronic use of statin therapy, presentation of acute coronary syndromes and one-year mortality after an incident acute coronary event Int J Cardiol 163 2013 102 104
8. A. Kuznik, and J. Mardekian Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the US diabetic population, 1999-2008 Cardiovasc Diabetol 10 2011 31
9. A. Kuznik, J. Mardekian, and L. Tarasenko Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010 BMC Nephrol 14 2013 132
10. M. Eliasson, U. Janlert, and J.H. Jansson et al. Time trends in population cholesterol levels 1986-2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study J Intern Med 260 2006 551 559
11. J. Ferrieres, V. Bongard, and J. Dallongeville et al. Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007 Arch Cardiovasc Dis 102 2009 293 301
12. M. Grau, I. Subirana, and R. Elosua et al. Trends in cardiovascular risk factor prevalence (1995-2000-2005) in northeastern Spain Eur J Cardiovasc Prev Rehabil 14 2007 653 659
13. V. Bongard, J. Dallongeville, and D. Arveiler et al. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study Arch Cardiovasc Dis 106 2013 93 102
14. Z. Reiner, A.L. Catapano, and G. De Backer et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
15. J. Ferrieres, V. Amber, and O. Crisan et al. Total lipid management and cardiovascular disease in the dyslipidemia international study Cardiology 125 2013 154 163
16. A.K. Gitt, H. Drexel, and J. Feely et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada Eur J Prev Cardiol 19 2012 221 230
17. J. Ferrieres, E. Berard, and O. Crisan et al. Residual dyslipidaemia after statin treatment in France: prevalence and risk distribution Arch Cardiovasc Dis 103 2010 302 309
18. B.A. Ference, W. Yoo, and I. Alesh et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis J Am Coll Cardiol 60 2012 2631 2639
19. M.J. Pletcher, K. Bibbins-Domingo, and K. Liu et al. Nonoptimal lipids commonly present in young adults and coronary calcium later in life: the CARDIA (Coronary Artery Risk Development in Young Adults) study Ann Intern Med 153 2010 137 146
20. N.J. Stone, J. Robinson, and A.H. Lichtenstein et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2013 10.1161/01.cir.0000437738.63853.7a
21. F. Taylor, M.D. Huffman, and A.F. Macedo et al. Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2013 CD004816
22. The Cochrane Database of Systematic Reviews-Issue 4 2013 J Evidence-Based Med 6 2013 115 116
23. World Health Organization English/French list of 182 non-governmental organizations in official relations with WHO reflecting decisions of EB128 2011 Available at: http://www.who.int/civilsociety/documents/NGOs-in-Official- Relations-with-WHO-2011-16-Mar-2011.pdf
24. F. Taylor, K. Ward, and T.H. Moore et al. Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 2011 CD004816
25. B. Mihaylova, J. Emberson, and L. Blackwell et al. The effects of lowering LDL-cholesterol with statin therapy in people at low-risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
26. F.C. Taylor, M. Huffman, and S. Ebrahim Statin therapy for primary prevention of cardiovascular disease JAMA 310 2013 2451 2452
27. N. Sattar, D. Preiss, and H.M. Murray et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
28. P.M. Kearney, L. Blackwell, and R. Collins et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
29. H. Naci, J. Brugts, and T. Ades Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246,955 participants from 135 randomized, controlled trials Circ Cardiovasc Qual Outcomes 6 2013 390 399
30. A. Kashani, C.O. Phillips, and J.M. Foody et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials Circulation 114 2006 2788 2797
31. A. Holbrook, M. Wright, and M. Sung et al. Statin-associated rhabdomyolysis: is there a dose-response relationship? Can J Cardiol 27 2011 146 151
32. E. Bruckert, G. Hayem, and S. Dejager et al. Mild to moderate muscular symptoms with high dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414
33. G.B. Mancini, S. Baker, and J. Bergeron et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference Can J Cardiol 27 2011 635 662
34. S.J. Semple Statin therapy, myopathy and exercise - a case report Lipids Health Dis 11 2012 40
35. B.A. Parker, A.L. Augeri, and J.A. Capizzi et al. Effect of statins on creatine kinase levels before and after a marathon run Am J Cardiol 109 2012 282 287
36. P. Mohassel, and A.L. Mammen Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies Muscle Nerve 48 2013 477 483
37. D.J. Graham, J.A. Staffa, and D. Shatin et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs JAMA 292 2004 2585 2590
38. P.D. Hamann, R.G. Cooper, and N.J. McHugh et al. Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum" Autoimmun Rev 12 2013 1177 1181
39. C. Lahaye, A.M. Beaufrere, and O. Boyer et al. Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins Joint Bone Spine 81 1 2014 79 82
40. L.M. Mangravite, B.E. Engelhardt, and M.W. Medina et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy Nature 502 2013 377 380
41. U. Laufs, W.S. Weintraub, and C.J. Packard Beyond statins: what to expect from add-on lipid regulating therapy? Eur Heart J 34 2013 2660 2665
42. J.C. Cohen, E. Boerwinkle, and T.H. Mosley Jr. et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
43. J.A. de Lemos, M.A. Blazing, and S.D. Wiviott et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
44. T.R. Pedersen, O. Faergeman, and J.J. Kastelein et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
45. C. Baigent, L. Blackwell, and J. Emberson et al. Efficacy and safety of more intensive lowering of LDL-cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
46. C.P. Cannon, E. Braunwald, and C.H. McCabe et al. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
47. J.C. LaRosa, S.M. Grundy, and D.D. Waters et al. Intensive lipid-lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
48. C.W. Nemerovski, F.D. Salinitri, and K.A. Morbitzer et al. Aspirin for primary prevention of cardiovascular disease events Pharmacotherapy 32 2012 1020 1035
49. C. Manes, L. Giacci, and A. Sciartilli et al. Aspirin overprescription in primary cardiovascular prevention Thromb Res 118 2006 471 477
50. J.B. Buse, H.N. Ginsberg, and G.L. Bakris et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association Diabetes Care 30 2007 162 172
51. J. Belch, A. MacCuish, and I. Campbell et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 2008 a1840
52. H. Ogawa, M. Nakayama, and T. Morimoto et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 2008 2134 2141
53. S.R. Seshasai, S. Wijesuriya, and R. Sivakumaran et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials Arch Intern Med 172 2012 209 216
54. F.H. Messerli, S. Bangalore, and S. Julius Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension Circulation 117 2008 2706 2715 discussion 15
55. B.M. Psaty, T. Lumley, and C.D. Furberg et al. Health outcomes associated with various anti-hypertensive therapies used as first-line agents: a network meta-analysis JAMA 289 2003 2534 2544
56. C.S. Wiysonge, H.A. Bradley, and J. Volmink et al. Beta-blockers for hypertension Cochrane Database Syst Rev 11 2012 CD002003
57. S. Mora, R.J. Glynn, and J. Hsia et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials Circulation 121 2010 1069 1077
58. P.M. Ridker The JUPITER trial: results, controversies, and implications for prevention Circ Cardiovasc Qual Outcomes 2 2009 279 285
59. Z. Reiner Statins in the primary prevention of cardiovascular disease Nat Rev Cardiol 10 2013 453 464
60. Haute Autorité de santé Annexes. Efficacité et efficience des hypolipemiants: une analyse centrée sur les statines 2010 Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/2010- 07/annexes-efficacite-et-efficience-des-hypolipemiants--une-analyse-centree-sur- les-statines.pdf
61. Améliorer la qualité du système de santé et maîtriser les dépenses: propositions de l'Assurance maladie pour 2014 Rapport au ministre chargé de la sécurité sociale et au Parlement sur l'évolution des charges et des produits de l'Assurance maladie au titre de 2014 (loi du 13 août 2004) 2014 Available at: http://www.apmnews.com/documents/110713-pt-III-C-amp-P.pdf
62. Haute Autorité de santé Évaluation des technologies de santé: analyse médico-économique. Évaluation par classe des médicaments antihypertenseurs 2013 Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-05/ rapport-evaluation-medicaments-antihypertenseurs.pdf
63. T.P. van Staa, L. Smeeth, and E.S. Ng et al. The efficiency of cardiovascular risk assessment: do the right patients get statin treatment? Heart 99 2013 1597 1602
64. J.P. Greving, F.L. Visseren, and G.A. de Wit et al. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis BMJ 342 2011 d1672
65. L. Grimaldi-Bensouda, M. Rossignol, and N. Danchin et al. Real-life effectiveness of statins in the prevention of first acute coronary syndrome in France: a prospective observational study Int J Cardiol 169 2013 271 275
66. I. Durack-Bown, P. Giral, and J.F. d'Ivernois et al. Patients' and physicians' perceptions and experience of hypercholesterolaemia: a qualitative study Br J Gen Pract 53 2003 851 857
67. M. Franciosi, F. Pellegrini, and G. De Berardis et al. Impact of physicians' beliefs and practices on cholesterol levels in patients with type 2 diabetes: a longitudinal assessment Am Heart J 149 2005 104 111
68. B. McGinnis, K.L. Olson, and D. Magid et al. Factors related to adherence to statin therapy Ann Pharmacother 41 2007 1805 1811
69. J.J. Ellis, S.R. Erickson, and J.G. Stevenson et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations J Gen Intern Med 19 2004 638 645
70. M.A. Huser, T.S. Evans, and V. Berger Medication adherence trends with statins Adv Ther 22 2005 163 171
71. International Society for Pharmaco-economics Outcomes Research ISPOR Medication Compliance and Persistence Special Interest Group 2008 Available at: http://www.ispor.org/sigs/medication.asp [accessed date: 15 May 2008]
72. D.F. Blackburn, R.T. Dobson, and J.L. Blackburn et al. Cardiovascular morbidity associated with non-adherence to statin therapy Pharmacotherapy 25 2005 1035 1043
73. L. Degli Esposti, S. Saragoni, and P. Batacchi et al. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis Clin Ther 34 2012 190 199
74. L. Wei, T.M. MacDonald, and A.D. Watson et al. Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study Pharmacoepidemiol Drug Saf 16 2007 385 392
75. D.M. Mann, M. Woodward, and P. Muntner et al. Predictors of non-adherence to statins: a systematic review and meta-analysis Ann Pharmacother 44 2010 1410 1421
76. V. Fung, F. Sinclair, and H. Wang et al. Patients' perspectives on non-adherence to statin therapy: a focus-group study Perm J 14 2010 4 10
77. D.M. Mann, J.P. Allegrante, and S. Natarajan et al. Predictors of adherence to statins for primary prevention Cardiovasc Drugs Ther 21 2007 311 316
78. T.N. Harrison, S.F. Derose, and T.C. Cheetham et al. Primary non-adherence to statin therapy: patients' perceptions Am J Manag Care 19 2013 e133 e139